{"id":224647,"date":"2025-10-19T07:42:19","date_gmt":"2025-10-19T07:42:19","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/224647\/"},"modified":"2025-10-19T07:42:19","modified_gmt":"2025-10-19T07:42:19","slug":"pfizers-q3-2025-earnings-what-to-expect","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/224647\/","title":{"rendered":"Pfizer\u2019s Q3 2025 Earnings: What to Expect"},"content":{"rendered":"\n<p class=\"yf-1090901\">With a market cap of\u00a0$139.4 billion, Pfizer Inc. (PFE)\u00a0is a global biopharmaceutical company headquartered in New York, known for developing and manufacturing medicines and vaccines across areas such as oncology, immunology, and infectious diseases. Its key products include Comirnaty, Paxlovid, Eliquis, and Ibrance.<\/p>\n<p class=\"yf-1090901\">The pharma titan is slated to announce its fiscal\u00a0Q3 2025\u00a0results before the market opens on Tuesday, Nov. 4. Ahead of the event, analysts predict\u00a0Pfizer to report an\u00a0adjusted EPS of $0.68, down 35.9% from\u00a0$1.06 in the year-ago quarter. However, the company has surpassed Wall Street&#8217;s bottom-line estimates in the past four quarterly reports.<\/p>\n<p class=\"yf-1090901\">For fiscal 2025, analysts expect\u00a0the drugmaker to report adjusted EPS of $3.07, down 1.3% from\u00a0$3.11 in fiscal 2024. Nevertheless, adjusted EPS is anticipated to grow 2.6% year-over-year to $3.15 in fiscal 2026.<\/p>\n<p>    <img fetchpriority=\"high\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"www.barchart.com\" loading=\"eager\" height=\"500\" width=\"767\" class=\"yf-1gfnohs loader\"\/> www.barchart.com      <\/p>\n<p class=\"yf-1090901\">Shares of\u00a0Pfizer\u00a0have dropped 8.2%\u00a0over the past 52 weeks, lagging behind both the S&amp;P 500 Index&#8217;s ($SPX)\u00a011.9% rise\u00a0and the Health Care Select Sector SPDR Fund&#8217;s (XLV)\u00a07.1% decrease\u00a0over the same period.<\/p>\n<p>    <img decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"www.barchart.com\" loading=\"lazy\" height=\"526\" width=\"782\" class=\"yf-1gfnohs loader\"\/> www.barchart.com      <\/p>\n<p class=\"yf-1090901\">On Oct. 6, Pfizer\u00a0shares surged 7.2% after the company announced a landmark agreement with the U.S. government to lower prescription drug prices. The deal includes \u2018most-favored-nation\u2019 pricing for Medicaid, 50% average discounts through a government website, and a $70 billion investment in U.S. research and manufacturing, providing a three-year tariff grace period and easing policy uncertainty for the pharmaceutical sector.<\/p>\n<p class=\"yf-1090901\">Analysts&#8217;\u00a0consensus rating on\u00a0Pfizer\u00a0stock\u00a0is moderately optimistic, with a &#8220;Moderate Buy&#8221; rating overall. Among 24 analysts covering the stock, six recommend a &#8220;Strong Buy,\u201d one has a &#8220;Moderate Buy&#8221; rating, 16 give a &#8220;Hold&#8221; rating, and one suggests a &#8220;Strong Sell.\u201d The stock\u2019s mean price target of $28.48 implies an upswing of 16.8% from the prevailing price levels.<\/p>\n<p class=\"yf-1090901\"> On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally\u00a0published on <a href=\"https:\/\/www.barchart.com\/story\/news\/35488959\/pfizers-q3-2025-earnings-what-to-expect?utm_source=yahoo&amp;utm_medium=syndication&amp;utm_content=footer_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Barchart.com;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Barchart.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"With a market cap of\u00a0$139.4 billion, Pfizer Inc. (PFE)\u00a0is a global biopharmaceutical company headquartered in New York, known&hellip;\n","protected":false},"author":2,"featured_media":224648,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,136188,137,500,2166,4337],"class_list":{"0":"post-224647","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-au","9":"tag-australia","10":"tag-biopharmaceutical-company","11":"tag-health","12":"tag-healthcare","13":"tag-infectious-diseases","14":"tag-pfizer-inc"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/224647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=224647"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/224647\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/224648"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=224647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=224647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=224647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}